[1]Kibrit J,Khan R,Jung BH,et al. Clinical assessment and management of portal hypertension. Semin Intervent Radiol,2018,35(3):153-159. [2]卢琳琳. 门脉高压症的治疗进展. 实用肝脏病杂志,2012,6(15):597-598. [3]Kimer N,Wiese S, Mo S,et al. Advances in the treatment of portal hypertension in cirrhosis. Expert Rev Gastroenterol Hepatol,2016,10(8):961-969. [4]Ju C,Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol,2016,13:316-327. [5]Oishi Y,Manabe I. Macrophages in inflammation, repair and regeneration. Int Immunol,2018,30(11):511-528. [6]Gomez Perdiguero E,Klapproth K Schulz C,et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature,2015,518(7540):547-551. [7]Steib CJ. Kupffer cell activation and portal hypertension. Gut,2011,60(10):1307-1308. [8]Rooijen NV,Kesteren-Hendrikx EV.“In vivo” depletion of macrophages by liposome-mediated “suicide”. Methods Enzymol,2003,373:3-16. [9]Yokoyama Y,Xu H,Kresge N,et al. Role of Thromboxane A2 in early BDL-induced portal hypertension. Am J Physiol Gastrointest Liver Physiol,2003,284(3):G453-460. [10]Vilaseca M,Guixe-Muntet S,Fernandez-Iglesias A,et al. Advances in therapeutic options for portal hypertension. Therap Adv Gastroenterol,2018,11:1-19. [11]Bosch J,Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatol Int,2018,12(Suppl 1):1-10. [12]Holland-Fischer H,Gronbaek H,Sandahl TD,et al. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut,2011,60(10):1389-1393. [13]Rooijen NV,Sanders A. Liposome mediated depletion of macrophages:mechanism of action, preparation of liposomes and applications. J Immunol Methods,1994,174(1-2):83-93. [14]Bennett CL,Clausen BE. DC ablation in mice: promises, pitfalls, and challenges. Trends Immunol,2007,28(12):525-531. [15]Weaver LK,Hintz-Goldstein KA,Pioli PA,et al.Pivotal advance:activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol,2006,80(1):26-35. [16]Moestrup SK,Moller HJ. CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response.Ann Med,2004,36(5):347-354. [17]Jing W,Ye Y,Ying Y,et al. Expression of serum sCD163 in patients with liver diseases and inflammatory disorders.Int J Clin Exp Pathol,2015,8(7):8419-8425. [18]Gronbaek H,Sandahl TD,Mortensen C,et al. Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosis. Aliment Pharmacol Ther,2012,36(2):173-180. [19]Iwakiri Y. Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase.Clin Mol Hepatol,2015,21(4):319. [20]Kajita M,Murata T,Horiguchi K,et al. iNOS expression in vascular resident macrophages contributes to circulatory dysfunction of splanchnic vascular smooth muscle contractions in portal hypertensive rats.Am J Physiol Heart Circ Physiol,2010,300(3):H1021-1031. [21]Zhao X, Deng B, Xu XY,et al. Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis.World J Gastroenterol,2013,19(36):6069-6076. |